SCHEMBL8528829

SCHEMBL8528829

Nc1ccc(NC(=O)c2ccccc2)c(O)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.69
CYP1A2 P05177 1/20 0.69
CYP2C9 P11712 1/20 0.69
CYP2C19 P33261 1/20 0.69
HDAC1 Q13547 6/20 0.58
MEN1 O00255 4/20 0.58
KMT2A Q03164 4/20 0.58
HDAC2 Q92769 3/20 0.57
HDAC3 O15379 2/20 0.57
MAPK1 P28482 2/20 0.57
SMN1; SMN2 Q16637 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
HSD17B10 Q99714 1/20 0.56
KCNMA1 Q12791 2/20 0.54
GAA P10253 3/20 0.53
PKM P14618 1/20 0.51
GRIK1 P39086 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
HCAR3 P49019 1/20 0.49
MMP14 P50281 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28803930 0.85 MAPT (0.52) MAPTCYP1A2CYP2C9CYP2C19HDAC1
SCHEMBL11591501 0.85 HDAC1 (0.71) MAPTCYP1A2CYP2C9CYP2C19HDAC1
SCHEMBL14428130 0.84 MAPT (0.57) MAPTCYP1A2CYP2C9CYP2C19HDAC1
SCHEMBL5395767 0.84 KMT2A (0.62) MAPTCYP1A2CYP2C9CYP2C19HDAC1
SCHEMBL3529060 0.83 MAPT (0.82) MAPTCYP1A2CYP2C9CYP2C19HDAC1
SCHEMBL29088261 0.83 MAPT (0.69) MAPTCYP1A2CYP2C9CYP2C19HDAC1
SCHEMBL28589438 0.83 MEN1 (0.67) MAPTCYP1A2CYP2C9CYP2C19HDAC1
SCHEMBL22905311 0.83 HDAC1 (0.71) MAPTHDAC1MEN1KMT2AHDAC2
SCHEMBL10011045 0.83 KCNMA1 (0.57) MAPTHDAC1MEN1KMT2AHDAC2
SCHEMBL5178629 0.82 HDAC1 (0.69) MAPTCYP1A2CYP2C9CYP2C19HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197533-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds ANADYS PHARMACEUTICALS, INC. (US) 2007-08-23 US disclosed
US-7223759-B2 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds ANADYS PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-5834166-A IMPROVED PHOTOSTABILITY EASTMAN KODAK COMPANY (US) 1998-11-10 US disclosed
US-4368257-A DIACYLAMINO-TYPE COUPLER KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1983-01-11 US disclosed
US-4362810-A DEVELOPMENT, SILVER HALIDE EMULSIONS KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1982-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197533-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds DDC, DPP3, AMPD3 MAPT 2536/4885CYP1A2 1210/4885CYP2C9 1056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.